Stanford S. Jhee

2.2k total citations
57 papers, 879 citations indexed

About

Stanford S. Jhee is a scholar working on Pharmacology, Physiology and Psychiatry and Mental health. According to data from OpenAlex, Stanford S. Jhee has authored 57 papers receiving a total of 879 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pharmacology, 13 papers in Physiology and 13 papers in Psychiatry and Mental health. Recurrent topics in Stanford S. Jhee's work include Cholinesterase and Neurodegenerative Diseases (12 papers), Alzheimer's disease research and treatments (9 papers) and Computational Drug Discovery Methods (7 papers). Stanford S. Jhee is often cited by papers focused on Cholinesterase and Neurodegenerative Diseases (12 papers), Alzheimer's disease research and treatments (9 papers) and Computational Drug Discovery Methods (7 papers). Stanford S. Jhee collaborates with scholars based in United States, United Kingdom and South Korea. Stanford S. Jhee's co-authors include Neal R. Cutler, Larry Ereshefsky, Thomas Shiovitz, Aaron W. Crawford, John J. Sramek, Brett A. English, Marcus J. Dortch, Hakop Gevorkyan, Thomas Langenickel and Parasar Pal and has published in prestigious journals such as SHILAP Revista de lepidopterología, Biological Psychiatry and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Stanford S. Jhee

57 papers receiving 826 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stanford S. Jhee United States	16	271	253	247	128	114	57	879
Robert A. Swarm United States	11	498 1.8×	245 1.0×	203 0.8×	76 0.6×	136 1.2×	26	1.0k
Almudena Areosa Sastre United Kingdom	8	409 1.5×	259 1.0×	508 2.1×	78 0.6×	125 1.1×	9	1.5k
Neda Minakaran United Kingdom	7	326 1.2×	282 1.1×	378 1.5×	37 0.3×	137 1.2×	19	1.1k
Mary Pat Knadler United States	22	194 0.7×	602 2.4×	334 1.4×	107 0.8×	132 1.2×	44	1.5k
Klaus Häger Germany	17	549 2.0×	270 1.1×	233 0.9×	119 0.9×	63 0.6×	52	1.8k
Joseph M. Scavone United States	21	258 1.0×	306 1.2×	248 1.0×	43 0.3×	128 1.1×	44	1.3k
Alice I. Nichols United States	20	179 0.7×	504 2.0×	212 0.9×	37 0.3×	114 1.0×	42	1.2k
D. R. Stanski United States	18	222 0.8×	295 1.2×	143 0.6×	293 2.3×	155 1.4×	58	1.8k
Gavrilova Si Russia	14	447 1.6×	280 1.1×	384 1.6×	66 0.5×	109 1.0×	116	1.3k
Stanley W. Carson United States	21	62 0.2×	181 0.7×	159 0.6×	75 0.6×	98 0.9×	54	1.3k

Countries citing papers authored by Stanford S. Jhee

Since Specialization

Citations

This map shows the geographic impact of Stanford S. Jhee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stanford S. Jhee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stanford S. Jhee more than expected).

Fields of papers citing papers by Stanford S. Jhee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stanford S. Jhee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stanford S. Jhee. The network helps show where Stanford S. Jhee may publish in the future.

Co-authorship network of co-authors of Stanford S. Jhee

This figure shows the co-authorship network connecting the top 25 collaborators of Stanford S. Jhee. A scholar is included among the top collaborators of Stanford S. Jhee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stanford S. Jhee. Stanford S. Jhee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lee, Nora, et al.. (2022). A Randomized, Double-Blind, Placebo- and Active-Controlled, Escalating Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Subcutaneous Eflapegrastim in Healthy Japanese and Caucasian Subjects. Drugs in R&D. 22(1). 71–87. 2 indexed citations

Hong, Jeong Hee, et al.. (2019). A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson’s disease, in healthy volunteers. SHILAP Revista de lepidopterología. 1 indexed citations

Gertsik, Lev, et al.. (2019). Implementing a Memory Clinic Model to Facilitate Recruitment into Early Phase Clinical Trials for Mild Cognitive Impairment and Alzheimer's Disease. The Journal of Prevention of Alzheimer s Disease. 6(2). 135–138. 4 indexed citations

Tseng, Jack, Marissa F. Dockendorf, Gopal Krishna, et al.. (2012). P1‐221: Safety and pharmacokinetics of the novel BACE inhibitor MK‐8931 in healthy subjects following single‐ and Multiple‐Dose administration. Alzheimer s & Dementia. 8(4S_Part_5). 3 indexed citations

Ereshefsky, Larry, et al.. (2009). P3‐243: The role for CSF dynabridging studies in developing new therapies for Alzheimer's disease. Alzheimer s & Dementia. 5(4S_Part_14). 5 indexed citations

Soares, Holly, Dane Liston, Karen J. Coffman, et al.. (2009). P1‐259: Aβ variability and effect of gamma secretase inhibition on cerebrospinal fluid levels of Aβ in healthy volunteers. Alzheimer s & Dementia. 5(4S_Part_8). 8 indexed citations

Jhee, Stanford S., Laura Fabbri, Susan Moran, et al.. (2003). First Clinical Evaluation of Ganstigmine in Patients With Probable Alzheimer's Disease. Clinical Neuropharmacology. 26(3). 164–169. 6 indexed citations

Jhee, Stanford S., et al.. (2003). Delayed Onset of Oculogyric Crisis and Torticollis with Intramuscular Haloperidol. Annals of Pharmacotherapy. 37(10). 1434–1437. 11 indexed citations

Hossain, Mohammad Sharif, Stanford S. Jhee, Thomas Shiovitz, et al.. (2002). Estimation of the Absolute Bioavailability of Rivastigmine in Patients with Mild to Moderate Dementia of the Alzheimer???s Type. Clinical Pharmacokinetics. 41(3). 225–234. 50 indexed citations

10.

Jhee, Stanford S., Thomas Shiovitz, Aaron W. Crawford, & Neal R. Cutler. (2001). Pharmacokinetics and Pharmacodynamics of the Triptan Antimigraine Agents. Clinical Pharmacokinetics. 40(3). 189–205. 87 indexed citations

11.

Cutler, Neal R., Stanford S. Jhee, Pamela Cyrus, et al.. (1998). Safety and tolerability of metrifonate in patients with alzheimer's disease: Results of a maximum tolerated dose study. Life Sciences. 62(16). 1433–1441. 15 indexed citations

12.

Cutler, Neal R., Daniel E. Salazar, Stanford S. Jhee, et al.. (1998). Pharmacokinetics and Pharmacodynamics of Avitriptan in Patients With Migraine After Oral Dosing. Headache The Journal of Head and Face Pain. 38(6). 446–452. 5 indexed citations

13.

Sramek, John J., Michael A. Eldon, Edward L. Posvar, et al.. (1998). Initial safety, tolerability pharmacodynamics, and pharmacokinetics of CI-1007 in patients with schizophrenia.. PubMed. 34(1). 93–9. 8 indexed citations

14.

Sramek, John J., et al.. (1997). Two Rapid-Dose Titrations of Sertindole in Patients With Schizophrenia. Journal of Clinical Psychopharmacology. 17(5). 419–422. 9 indexed citations

15.

Sramek, John J., Marilyn Gaston, Stanford S. Jhee, et al.. (1996). Establishing the Maximum Tolerated Dose of Lesopitron in Patients With Generalized Anxiety Disorder. Journal of Clinical Psychopharmacology. 16(6). 454–458. 8 indexed citations

16.

Anders, Robert J., Stanford S. Jhee, John J. Sramek, et al.. (1995). Placebo-controlled evaluation of three doses of a controlled-onset, extended-release formulation of verapamil in the treatment of stable angina pectoris. The American Journal of Cardiology. 75(16). 1102–1106. 35 indexed citations

17.

Jhee, Stanford S., et al.. (1995). Orthostasis in Alzheimer Disease. Alzheimer Disease & Associated Disorders. 9(4). 243–246. 4 indexed citations

18.

Jhee, Stanford S., et al.. (1994). Stability of paclitaxel with ondansetron hydrochloride or ranitidine hydrochloride during simulated Y-site administration. American Journal of Health-System Pharmacy. 51(9). 1201–1204. 4 indexed citations

19.

Fox, Janet L., et al.. (1994). Stability of ranitidine hydrochloride with ondansetron hydrochloride or fluconazole during simulated Y-site administration. American Journal of Health-System Pharmacy. 51(3). 391–394. 1 indexed citations

20.

Choi, Jun‐Shik, et al.. (1994). Stability of paclitaxel and fluconazole during simulated Y-site administration. American Journal of Health-System Pharmacy. 51(21). 2704–2706. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact